Angiogenesis is essential for development and tumor progression. With the aim of identifying new compound inhibitors of the angiogenesis process, we used an established enhanced green fluorescent protein-transgenic zebrafish line to develop an automated assay that enables high-throughput screening of compound libraries in a whole-organism setting. Using this system, we have identified novel kinase inhibitor compounds that show anti-angiogenic properties in both zebrafish in-vivo system and in human endothelial cell in-vitro angiogenesis models. Furthermore, we have determined the kinase target of these compounds and have identified and validated a previously uncharacterized involvement of phosphorylase kinase subunit G1 (PhKG1) in angiogenesis in vivo. In addition, we have found that PhKG1 is upregulated in human tumor samples and that aberrations in gene copy number of PhK subunits are a common feature of human tumors. Our results provide a novel insight into the angiogenesis process, as well as identify new potential targets for anti-angiogenic therapies.
Introduction
The formation of the first primitive vessels from mesoderm-derived angioblasts (endothelial precursor cells) occurs through the vasculogenesis process. Later growth of both physiological and pathological vessels occurs through angiogenesis, which is the process of growth of microvessels from existing vasculature (Eilken and Adams, 2010) . Pathological angiogenesis is associated with tumor progression and is a pre-requisite of tumor growth and metastasis (Carmeliet and Jain, 2000) . Therefore, inhibitors of angiogenesis are desirable candidates for anti-tumoral therapies, and angiogenic factors that diffuse from tumor cells to stimulate angiogenesis have been extensively investigated as therapeutic targets. A number of inhibitors of angiogenic factors are currently undergoing phase III clinical trials. Several such compounds are kinase inhibitors, suggesting that kinase inhibition represents a relevant and effective approach. Recently, a number of antiangiogenic compounds have been approved by the US Food and Drug Administration for therapeutic use (Gragoudas et al., 2004; Hurwitz et al., 2004; Folkman, 2007) .
Zebrafish provide a useful vertebrate model organism due to their high fecundity, short-generation times, and ease of housing and maintaining large numbers, which provides them with statistical power and adaptability to high-throughput systems that are impossible with mammalian models. Furthermore, there is a high degree of conservation between zebrafish and other species regarding the pathways involved in tumorigenesis (including many tumor suppressor pathways such as the p53 (Berghmans et al., 2005) , phosphatase and tensin homolog (Faucherre et al., 2008) , retinoblastoma protein (pRB) (Edmunds et al., 2002) , lkb (Marshall et al., 2011) , etc) and angiogenesis (Lyons et al., 1998; Liang et al., 2001) . Zebrafish have therefore emerged as an effective model for cancer studies as well as a valuable screening tool as they offer the biological complexity of an in vivo system, whilst meeting the requirement for large numbers and efficient drug uptake from the water (Parng et al., 2002; Kidd and Weinstein, 2003) . Furthermore, they present powerful imaging solutions through in-vivo fluorescent labeling of desired organs, such as the vasculature system. Several successful screens have been performed in zebrafish, including two screens directed at compound inhibitors of angiogenesis (Tran et al., 2007; Wang et al., 2010) .
In this study, we have taken advantage of the TG(Fli1:EGFP) zebrafish line (Lawson and Weinstein, 2002) , in which the vascular system is visible through endothelial-specific enhanced green fluorescent protein (EGFP) expression, to screen putative kinase inhibitors from the BioFocus SoftFocus library SFK33 (Galapagos, BV, Leiden, The Netherlands) to identify inhibitors of angiogenesis. We have developed an automated assay to enable high-throughput compound screening and have identified anti-angiogenic compounds, two of which were further studied to elucidate the antiangiogenic mechanism. Furthermore, we have identified phosphorylase kinase (PhK) as a target and verified its involvement in angiogenesis and value as a potential target for anti-tumoral therapeutics.
Results
In zebrafish, the process of angiogenesis drives the formation and sprouting of the intersegmental vessels (ISV) from the vasculogenic vessels of the dorsal aorta (DA) between 16-19 h post fertilization (hpf; Isogai et al., 2001) . A labeled diagram outlining the vasculature of the TG(Fli1:EGFP) zebrafish line is provided in Supplementary Figure 1 .
To discover new inhibitory compounds of the angiogenesis process, an automatic quantitative screening assay was developed using embryos from the TG(Fli1:EGFP) zebrafish line. The assay was implemented in a high-throughput screening platform (Biobide SL, San Sebastia´n, Spain) and includes automated methods for embryo dispensation, compound delivery, embryo imaging and processing of the results (details of automated methods are provided elsewhere, (Letamendia et al., submitted). Treated embryos were imaged and automatically analyzed for defects in ISVs development by measuring the fluorescence area in the embryo tail. A detailed analysis to quantify the effects on the total number of ISVs formed, as well as the number of complete ISVs formed (that is, the number of ISVs that reach the dorsal longitudinal anastomotic vessel uninterrupted), was carried out for the positive compounds. Following an initial screen of 288 compounds, seven compounds were identified that showed dose-dependent anti-angiogenic activity with low toxicity, giving a hit rate of just under 2.5%. The data obtained for compounds F10 and F11 is shown in Figure 1 . For each compound, an image acquired at the concentration at which a statistically significant decrease in ISV formation is detected is shown (Figures 1a and d) , and the decrease in total ISV formation (Figures 1b and e) and in the number of complete ISVs formed (Figures 1c  and f) is plotted against the specific concentrations titrated. The data for the other 'hit' compounds is similarly provided in Supplementary Figures 2, 3 and 4 .
The BioFocus SoftFocus library contains compounds that are selected as putative kinase inhibitors based on their structure. To elucidate the targets of the compounds isolated from our screen, in-vitro kinase profiling was performed on compounds that were identified as inhibitors of angiogenesis (Supplementary Figure 5) . Kinase profiling identified PhK subunit G1 (PhKG1) as the kinase target of compound F11 (that is, showing less than 10% activity in the kinase profiling assay). Interestingly, PhKG1 was also inhibited by compound F10, albeit with weaker effect, among other kinases including TrKA and PIM1 (Supplementary Figure 5A) . No kinase was inhibited to less than 10% activity by compound F10, indicating a less specific effect of this compound compared with F11. Careful titration of each compound under the kinase profiling conditions would allow a more accurate analysis of the difference in efficacy of each compound for PhKG1; however, the higher apparent toxicity level of F10, evident by comparing the overall appearance of the embryo at 10 mM F10 with 30 mM F11 (Figure 1 ), would support a more pleiotropic nature of this compound. These two compounds were taken forward for further studies and for validation of the kinase targets (the chemical structures of compounds F10 and F11 are shown in Supplementary Figure 5B) .
To confirm that these two compounds inhibited specifically the angiogenic process of ISV sprouting, as opposed to inhibition of general vasculogenesis, embryos were treated at 10 hpf, before the vasculogenic vessels had formed. An overnight treatment with 5 mM of either drug at this time point lead to almost complete inhibition of ISV growth with no inhibitory effect on the DA, confirming that normal vasculogenic processes, by which the DA is formed, were not affected by either compound (Supplementary Figure 6A) , despite the strong effect observed on ISV sprouting, which is an angiogenic process. In addition, treatment with the compounds at 3 days post fertilization (dpf) had no effect on the preexisting ISV (Supplementary Figure 6B) , confirming that the compounds specifically inhibit the angiogenic process and do not target established blood vessels.
To study the effect of our compounds in a human cellbased in vitro test for angiogenesis, a basic assay of human umbilical vein endothelial cell (HUVEC) tube formation was performed (Figures 2a and b) . A dosedependent reduction in tube formation was observed in the presence of either compound, with an approximate IC 50 of 6 mM for F10 and 20 mM for F11 (Figures 2a and b) , indicating that both compounds have antiangiogenic effect on human endothelial cells.
HUVEC cell migration was also assessed upon treatment with each compound using a transwell migration assay (BD Biosciences, Bedford, MA, USA). A dose-dependent reduction in the number of cells that migrated was observed in the presence of each compound (IC 50 ¼ 1.5 mM for both compounds; Figures 2c and d), indicating a strong inhibitory effect of both compounds on HUVEC cell migration.
Additionally, a cell proliferation assay was performed to assess the effect of each compound on HUVEC proliferation. A concentration range of 1-50 mM of each compound was tested and dose-dependent decrease in cell proliferation was observed in the presence of compound F10 above a concentration of 7 mM (Figure 2e ). However, the proliferation rate never decreased to below 50% of the untreated activity and no effect on proliferation or viability is observed at either 1.5 mM (the IC 50 of HUVEC cell migration inhibition) or 6 mM (the IC 50 of HUVEC tube formation inhibition). No decrease in cell proliferation was observed in the presence of compound F11 (Figure 2e ), indicating that this compound does not inhibit HUVEC proliferation or show toxicity over the PhK functions as a regulator of angiogenesis S Camus et al concentration range tested. Therefore, the inhibition of tube formation and migration of HUVEC cells in the presence of either compound is not a result of decreased HUVEC proliferation or cell viability, indicating that the primary effect of the compounds is the suppression of endothelial cell function rather than cytotoxicity. To further confirm the anti-angiogenic properties of the two compounds, we performed a longer-term assay for studying the formation of capillary-like structures, as described in Supplementary Materials and Methods. The HUVEC cells initially form small islands within the culture matrix, but enter a migratory phase, resulting in thread-like tubule structures upon proliferation. After 8-11 days, they form a branched network of anastomosing tubules in a process that more closely resembles physiological angiogenesis. Two days after the cells were seeded, they were treated with either compound F10 or F11, at the indicated concentrations ( Figure 3) . A dosedependent reduction in tube formation was observed with both compounds following 11 days of treatment, and both compounds completely inhibited capillary formation at 5 mM.
Having identified PhKG1 as the kinase target of compound F11 and a potential target of compound F10, we wished to analyze the involvement of PhKG1 in the anti-angiogenic effects observed by treatment with these two compounds. To this end, we tested whether overexpression of PhKG1a (the ortholog of PhKG in zebrafish) could reduce the anti-angiogenic effect of the two compounds in zebrafish, an experiment that is analogous to situations in which a drug effect is overcome by increased gene copy number (Ferguson, 1991) . Treatment with low concentrations (suboptimal for strong ISV inhibition so that neither compound was saturating) of either compound caused a mild inhibition of ISV formation over a 24-h treatment. Injection of PhKG1a mRNA lead to at least partial rescue of ISV inhibition ( Figure 4 , percentages of embryos showing partial and complete rescue are shown to the right), suggesting that the inhibition of PhK by compounds F10 and F11 is an important factor in the antiangiogenic properties of both compounds and further highlighting the role of PhKG1 in angiogenesis.
To investigate the interaction between PhKG1 and compounds F10 and F11, we performed a threedimensional modeling analysis of the interaction site. Space-filling models of BioFocus SoftFocus compounds F10 and F11 docked into the catalytic site of PhKG1 are shown in Supplementary Figure 7A and 7B, respectively. The western part of the compounds is completely planar and fits snugly in the especially tight hinge region of PhKG1. The aminomethylene linker positions the eastern parts of the compounds well for further interactions with the protein. Two-dimensional cartoons of the interactions that compound F10 (Supplementary Figure 7C ) and F11 (Supplementary Figure 7D ) make with the protein are also provided. Both compounds accept a hydrogen bond from the NH group of Met106. One or two aromatic C-HyO hydrogen bonds (not indicated) can also be formed. The aromatic rings of both compounds are positioned such that several interactions can be formed between the backbone NH groups and the p-clouds of these aromatic rings. Compound F11 accepts a hydrogen bond from the side PhK functions as a regulator of angiogenesis S Camus et al chain amine of Lys48, whereas F10 does not. F11 also makes a tighter interaction with the hinge region (around Met106) than F10. These two effects combined may explain why F11 is somewhat more active than F10. The activity of these compounds combined with a unique binding mode provides a good starting point for compound optimization and further drug discovery efforts.
To further analyze the role of PhKG in angiogenesis, we employed specific morpholino knock down of PhKG1a in the TG(Fli1:EGFP) zebrafish line. Injection of PhKG1a-specific morpholino demonstrated that knock down of this kinase had a particularly marked effect on angiogenesis, with inhibition of ISV growth observed in at least 97% of injected embryos, compared with mock injected controls. PhKG1a knock down led to incomplete formation of all ISV and the complete failure of dorsal longitudinal anastomotic vessel formation ( Figure 5, upper panel) . To confirm the specificity of the phenotype observed, phenotypic rescue experiments were performed by co-injection of PhKG1a mRNA. Rescue by concurrent injection of PhKG1a mRNA was observed in over 80% of injected embryos ( Figure 5 , lower panels). No effect of PhKG1a mRNA alone was observed. This data strongly implicates a function of PhKG1a in the angiogenic process. This is the first report of PhKG1 being implicated in angiogenesis, identifying a novel potential target for the treatment of cancer by angiogenesis inhibition. No effect on ISV formation was observed in the presence of a mismatch control morpholino (in which five bases are substituted; Figure 5 , labeled Ctrl), further confirming the specificity of the effects observed.
Previous reports concerning PhK focus on its role during metabolism and concentrate on its expression in the liver. To determine if PhKG1a is expressed in zebrafish embryos during angiogenesis, we performed in situ hybridization with a PhKG1a-specific probe on Figure 8) . A strong PhKG1a-specific signal was observed along the DA (from which the ISVs sprout) at the 24 hpf stage (Supplementary Figure 8A) . Figure 8B) . A GFP control is included to clarify the vasculature structures and the timing of ISV sprouting and growth (Supplementary Figure 8C) . Incidentally, early expression of PhKG1a would coincide with the timing of morpholino activity and expression. Furthermore, the timing of PhKG1a mRNA expression is Figure 6A ) and their lack of activity when used to treat 3 dpf embryos (Supplementary Figure 6B ). To validate the role PhKG1 human cell-based angiogenesis assays, we performed tube formation, cell migration and proliferation assays in HUVEC cells in which PhKG1 was specifically knocked down by siRNA targeting (Figure 6 ). A 50% reduction in tube formation was observed in the presence of PhKG1-specific siRNA compared with the control siRNA (Figure 6a ). PhKG1 knockdown caused an even more striking reduction in cell migration, with five-fold fewer cells migrating in the presence of PhKG1-specific siRNA compared with control siRNA (Figure 6b) . No reduction in cell proliferation was observed (Figure 6c) , confirming that the effects were specific and not caused by general toxicity or reduced proliferation. The level of PhKG1 knockdown is shown in Figure 6d . The identification and validation of the compounds' target represents an important advancement on previous screens (in which compounds are often identified that have a strong effect on the desired screening parameter, but the mode of action is rarely elucidated), as it enables rational optimization of the compounds identified to increase their efficiency and specificity towards the target.
There are no previous reports of PhK involvement in cancer progression or angiogenesis. We were therefore interested to determine if there is a link between PhKG1 function and cancer. We therefore searched The Cancer Genome Atlas (TCGA) data (website retrieved through the CGWB website), which integrates publicly available cancer data from various projects, and compiled data of PhKG1 gene copy number in tumor samples (https:// cgwb.nci.nih.gov/). Interestingly, amplification of PhKG1 occurs in a high number of TCGA tumor samples tested (between 22-75%, depending on the tumor type; Table 1 ). PhK is a complex holoenzyme consisting of four different types of subunit, a, b, g and d.
Figure 5 PhKG1a knockdown in zebrafish inhibits angiogenic ISV formation. Single-cell stage embryos were injected with 0.2 of PhKG1a-specific morpholino or 0.2 mM of a control morpholino, in which five bases are substituted, as indicated (upper panels). The effects on ISV formation were assessed manually. The specificity of the PhKG1a morpholino was confirmed by co-injection of 0.5 or 5 pg of PhKG1a mRNA (lower panels), which leads to dosedependent rescue of ISV formation. Injection of 5 pg of PhKG1a mRNA alone had no effect (bottom panel). Percentages of injected embryos showing phenotype and phenotypic rescue are shown to the right of the panels. 
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PhKG1 (the g-subunit) is the catalytic subunit and upregulation of this subunit would lead to increasedPhK activity. The a-and b-subunits are inhibitory subunits that restrain the enzymatic activity. Downregulation of these subunits would thus also be expected to lead to increased PhK activity. We therefore analyzed if downregulation of PhK subunit-a (the largest of the regulatory subunits) is a common feature of the TCGA tumor samples analyzed and discovered that PhKa deletion (decreased copy number) is very common, with between 44-85% of tumor samples showing PhKa deletion (Table 1) . We then analyzed the correlation between PhKG1 amplification and PhKa deletion within individual tumors, determining the number of tumors that showed an anomaly in either subunit that would be expected to lead to increased-PhK activity (that is, either PhKG1 amplification or PhKa deletion). The total number of tumors that show an aberration in at least one of these subunits of the PhK holoenzyme is extremely high, ranging from 59% in ovarian serous cystadenocarcinoma to 97% of lung squamous cell carcinoma samples showing either an amplification of PhKG1 or deletion of PhKa, indicating that there is a strong link between PhK aberration and tumorigenesis. This highlights the relevance of PhK as a potential therapeutic target.
Having identified PhK as a kinase that shows a high incidence of gene copy number aberrations by TCGA copy number variation profiling, we were interested to establish a concrete correlation between copy number and mRNA levels. We therefore examined the incidence of gene copy number aberrations in commercially available cell lines, with which we could easily determine PhKG1 mRNA levels by quantitative PCR. Approximately 65% (135/207) of tumor cell lines tested in the GlaxoSmithkline Cancer Cell Line Genomic Profiling Data on the CGWB website (https://cgwb.nci.nih.gov/) showed an amplification of the mean copy number of the PhKG1 gene (Table 2) . To determine if this amplification translates into an increase in mRNA expression level, we chose five colon cancer cell lines, which represent a cancer type that has been approved for clinical trials of angiogenesis inhibitors, and performed quantitative PCR for PhKG1 levels. Two of the cell lines included, LS174T and Colo320 were shown by the GlaxoSmithkline analysis to have normal PhKG1 copy number, whereas SW620, Colo201 and NCIH747 were all shown to have some degree of PhKG1 copy number amplification. By quantitative PCR, we found a correlation between the published gene copy number and mRNA levels in four out of five of the cell lines tested, and that two cell lines, Colo201 and NCIH747, do indeed express high levels of PhKG1 mRNA compared with human fibroblast control or cancer cells with normal copy number of PhKG1 (approximately Bladder  8  10  80  Brain  3  7  43  Breast  16  21  76  CNS  7  11  64  Cervix  4  7  57  Colon  11  19  58  Kidney  5  8  63  Liver  5  9  56  Lung  54  79  68  Muscle  2  4  50  Ovary  5  7  71  Rectum  2  2  100  Sarcoma  1  2  50  Stomach  3  5  60  Thyroid  3  4  75  Uterus  4  9  44  Vulva  2  3  67  Total  135  207  65 Abbreviation: CGWB, Cancer Genome Work Bench; CNS, central nervous system; GSK, GlaxoSmithkline; PhKG1, phosphorylase kinase subunit G1. Data from GSK Cancer Cell Line Genomic Profiling Data on the CGWB website.
The number of cancer cell lines that show amplifications in the PhKG1 (PhKG1 amplification) gene copy number out of the total number of cell lines analyzed (Total) is shown. The final column expresses the same information as a percentage (the percentage of tumors that show PhKG1 amplification out of the total number analyzed). The data is shown for each individual cell line type (indicated in the first column), as well as across all of the cell lines combined (final row).
PhK functions as a regulator of angiogenesis S Camus et al five times and three times the control levels, respectively; Supplementary Figure 9 ). This data suggests that amplification of PhKG1 copy number does lead to an increase in PhKG1 mRNA expression levels in these lines. Furthermore, we examined the relative PhKG1 levels in a panel of different human tumor samples, obtained as a commercially available cDNA array. Using quantitative PCR, we discovered that PhKG1 mRNA levels are elevated by more than two-fold (green bars) in the majority of human tumors tested (Figure 7) . Interestingly, there was no upregulation of PhKG1 detected in prostate cancer, suggesting that PhKG1 upregulation, although common, is not a universal characteristic of all tumor types and that prostate cancer may not represent a type that would benefit from PhKG1 targeting. This data provides the first evidence of upregulated PhKG1 mRNA expression levels in a variety of human tumor types and suggests that an upregulation of PhKG1 could be associated with cancer progression.
Discussion
PhKG1 has not previously been implicated in either tumorigenesis or angiogenesis. We therefore provide here the first description of the involvement of PhK in the angiogenesis process and the first identification of PhK as a novel therapeutic target. Rescue of the phenotype observed under subsaturating concentrations of either compound by overexpression PhKG1 (through injection of mRNA) confirms that a component of the anti-angiogeneic effect of both compounds is dependent on inhibition of PhKG1. This rescue is analogous to drug resistance conferred by gene copy number amplification, such as clinical resistance to STI-571 due to amplifications in bcr-abl gene copy number (Gorre et al., 2001 ) and resistance to methotrexate in acute leukemia due to dihydrofolate reductase amplification (Carman et al., 1984; Goker et al., 1995) among others (Ferguson, 1991) . The level of rescue obtained in the presence of F10 was substantially lower than that observed in the presence of F11, which is likely to reflect the stronger inhibitory effect of compound F11 on PhKG1 and the more pleiotropic nature of compound F10 (from the profiling data). This pleiotropicity could also explain the increased toxicity observed in both the zebrafish whole organism models and the HUVEC WST-1 assay in the presence of compound F10. Few embryos showed complete rescue by PhKG1 overexpression (particularly in the case of F10), suggesting that there could be other kinases affected by the compounds, in keeping with the fact that these are early stage compounds that have not undergone any form of optimization. Other kinases that showed weak inhibition during the kinase profiling include TrKA and PIM1; inhibition of these additional kinases by F10 and F11 could therefore explain the incomplete phenotypic rescue observed upon overexpression of PhKG1 mRNA.
PhK is an (abgd) 4 holoenzyme that regulates glycogenolysis through phosphorylation, and thereby activation, of glycogen phosphorylase, which releases glucose 1-phosphate from glycogen, feeding into the glycolysis pathway to allow production of ATP. Glycogen phosphorylase is a fundamental enzyme in glycogen metabolism and PhK is the only enzyme known to catalyze its activation (Graves et al., 1999) . The link between metabolism and tumor progression currently represents an exciting direction in cancer research, as the importance of metabolic transformation for maintaining the tumorigenic state becomes clearer (for reviews, see Kroemer and Pouyssegur, 2008; Tennant et al., 2010) . Interestingly, the inhibition of key enzymes involved in glycogen metabolism has been shown to have a great effect on the angiogenic potential of HUVEC cells (Vizan et al., 2009) , indicating that inhibition of metabolic pathways could offer novel therapeutic approaches that target both the angiogenesis pathway, as well as inhibit the actual growth and maintenance of tumor cells themselves. Metabolic pathways are therefore becoming an increasingly popular area of research into novel pathways for therapeutic intervention Figure 7 PhKG1 is upregulated in human tumor samples from a range of tumor types. Q-PCR was performed using PhKG1-specific probes on duplicate TissueScan Cancer Survey cDNA arrays. Green bars indicate samples in which the PhKG1 mRNA level is more than two-fold the average PhKG1 level present in the tissue-matched normal tissue controls. Yellow bars indicate no change (that is, less than two-fold difference compared with the average PhKG1 level in the tissue-matched controls).
PhK functions as a regulator of angiogenesis S Camus et al (Cascante et al., 2010 Recently, there has been a shift towards 'rational' drug design, in which a drug is designed to target a specific protein or pathway known to be involved in tumorigenesis (Lane et al., 2010) . However, screening libraries vastly increases the number of candidate compounds to be discovered and in many ways is a much simpler and more cost effective approach. In light of the fact that we identify and validate the targets of our compounds, our results highlight the advances in technology that make high-throughput screening a valuable source of compound discovery and emphasize the value of zebrafish as a model organism that lends itself to high-throughput screening techniques, whilst providing very relevant screening parameters due to the whole-organism setting.
Here we identify kinase-inhibitor compounds that cause marked inhibition of angiogenesis in both zebrafish whole organisms and in human in vitro cell-based angiogenesis assays. Furthermore, we determine the kinase target, offering an important advancement on many previous screens in which the compound targets are not elucidated, and identify a previously undiscovered role of PhKG1 in angiogenesis. Our results provide the first evidence of the PhK holoenzyme having a role in tumorigenesis, offer further insight into the process of angiogenesis and establish PhKG1 as a novel anti-angiogenic therapeutic target.
Materials and methods
Zebrafish husbandry and compound screening Adult TG(Fli1:EGFP) zebrafish were housed and maintained in accordance with standard procedures. Screening was performed in an automatic HTS platform (Biobide), as described in Supplementary Materials and Methods. Kinase profiling was performed in The National Centre for Protein Kinase Profiling at the MRC Protein Phosphorylation Unit (Dundee, UK), and kinases that show less than 10% activity in the screen are considered to be compound targets.
Morpholino experiments
Specific morpholino against PhKG1a and the control morpholino (GeneTools LLC, Philomath, OR, USA) were reconstituted in RNAse-free water according to manufacturer's instructions. Volumes of 0.1-1 mM were titrated into single-cell embryos (n ¼ >100) and the lowest effective dose (0.2 mM) was used for all experiments. Zebrafish PhKG1a gene was cloned into pGEM-T vector using the pGEM-T easy Vector system I (Promega BioSciences, LLC. San Luis Obispo, CA, USA) according to manufacturer's instructions, and mRNA was synthesized using mMessage Machine (Ambion, Life Technologies, Grand Island, NY, USA). For the rescue of F10 and F11 phenotype by PhKG1a mRNA, embryos were injected at the single-cell stage with a titration of PhKG1 mRNA and treated with 3 mM of F10 or 5 mM of F11 at 24 hpf for 24 h. Rescue with 10 pg of PhKG1a mRNA for compound F10 and 20 pg mRNA for compound F11 is shown.
In situ hybridization was performed as described in (Pownall et al., 1996) . Sense and anti-sense probes were synthesized using the pGEMT PhKG1a plasmid template using mMessage Machine (Ambion).
HUVEC assays HUVEC cells were obtained from BD Biosciences and maintained at 37 1C with 5% CO 2 in endothelial cell culture medium (BD Biosciences). The basic tube formation assay was performed in a 96-well plate coated with ECMatrix (Millipore, Billerica, MA, USA), as previously described (Tran et al., 2007) . Cells were treated in triplicate with compound F10 or F11 (or dimethyl sulfoxide control), as indicated. Tubes were stained with fluorescent dye Calcein AM (Invitrogen, SA, Life Technologies, Grand Island, NY, USA) and imaged with a Leica fluorescence microscope (Leica Microsystems, Milton Keynes, UK).. The length of tubule extensions from cell bodies was measured using LAS AF software (Leica Microsystems) and the average total length from three fields of view per well was determined.
The HUVEC migration assay was performed using the transwell biocoat endothelial cell migration angiogenesis system (BD Biosciences), according to manufacturer's instructions. Cells were seeded into the upper chamber in the presence of a titration of F10 or F11 (or dimethyl sulfoxide control) in triplicate and endothelial growth medium containing 10% fetal calf serum was placed in the lower chamber as a chemoattractant. Calcein AM was added to the lower chamber and cells were imaged using a Leica fluorescence microscope. The number of migrated cells were counted and shown as an average of three fields per well.
A WST-1 Cell proliferation Assay (Roche Applied Science, Roche Diagnostics Ltd, Burgess Hill, UK) was performed according to manufacturer's instructions. Cells were seeded in a 96-well plate and treated with F10 or F11, in triplicate, as indicated. After 20 h of treatment, the WST-1 reagent was added. Absorbance was read at 450 nm on a BioTek PowerWave XS (BioTek Germany, Bad Friedrichshall, Germany) microtitre plate reader. siGENOME SMARTpool siRNA against PhKG1 and control siRNA (Thermo Fisher Scientific, Dharmacon Products, Lafayette, CA, USA) were transfected according to the Dharmcon HUVEC transfection protocol, using Dharma-FECT transfection reagent 4.
Quantitative PCR Total RNA was isolated from cell lines using Trizol (Invitrogen), followed by cDNA synthesis using Superscript II Reverse Transcriptase (Invitrogen). Quantitative PCR was performed on cDNA from cell lines using SYBR GREEN PCR Master Mix (Applied Biosystems, Life Technologies, Grand Island, NY, USA). Results were validated using two independent primer sets for human PhKG1. Q-PCR on duplicate
